With positive Keytruda data, Merck scrambles the market for lung cancer immunotherapies – STAT
STAT |
With positive Keytruda data, Merck scrambles the market for lung cancer immunotherapies
STAT n the latest twist in the immunotherapy market, Merck (MRK 1) disclosed that its Keytruda cancer medicine helped previously untreated lung cancer patients live longer than chemotherapy in a late-stage trial, which may solidify its position as the … Merck eyes best day since 2016, gains help fuel pharma rally Key Keytruda data drives Merck & Co up by 5% This Lung Cancer Drug Could Let Patients Forgo Chemo—And It's Sending Merck's Stock Soaring |
